BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Reboxetine

A morpholine derivative that is a selective and potent noradrenaline reuptake inhibitor; it is used in the treatment of DEPRESSIVE DISORDER.

298+ PubMed studies analyzed · 82 RCTs · Evidence Score: 55.9

Research Domains

Reboxetine has been studied across 20 research domains including 🌤️ Mood & Depression, 🧠 Focus & Attention, 🫘 Kidney, 🧘 Stress & Anxiety, 🧠 Memory. The primary research focus is 🌤️ Mood & Depression with 54% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Reboxetine, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Venlafaxine
3 shared targets
nomifensine
2 shared targets
methylphenidate
2 shared targets
nisoxetine
2 shared targets
milnacipran
2 shared targets
tenamfetamine
2 shared targets
midomafetamine
2 shared targets
desvenlafaxine
2 shared targets
esreboxetine
2 shared targets
levomilnacipran
2 shared targets
Loading evidence profile...

This evidence profile for Reboxetine is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.